GLP-1 Agonist List of Drugs: The Complete Catalog of FDA-Approved and Compounded Medications (2026)

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Nine GLP-1 receptor agonists are FDA-approved as of April 2026: exenatide, lixisenatide, liraglutide, dulaglutide, semaglutide (injectable and oral), tirzepatide, and two fixed-ratio combinations
• Semaglutide and tirzepatide dominate current prescribing, accounting for 78% of new GLP-1 starts in 2025 (IQVIA data)
• Compounded versions of semaglutide and tirzepatide are available during FDA shortage periods but are not FDA-approved and differ in formulation from brand products
• The functional differences between drugs come down to receptor selectivity (GLP-1 only vs dual GLP-1/GIP), half-life (daily vs weekly dosing), and delivery route (injection vs oral)

Direct answer (40-60 words)

As of April 2026, nine GLP-1 receptor agonists are FDA-approved: exenatide (Byetta, Bydureon), lixisenatide (Adlyxin), liraglutide (Victoza, Saxenda), dulaglutide (Trulicity), semaglutide (Ozempic, Wegovy, Rybelsus), tirzepatide (Mounjaro, Zepbound), and two fixed combinations. Compounded semaglutide and tirzepatide are available but not FDA-approved.

Table of contents

1. The complete FDA-approved GLP-1 agonist list
2. The functional classification system: short-acting vs long-acting vs dual agonists
3. Semaglutide and tirzepatide: why these two dominate prescribing
4. Compounded GLP-1 medications: what they are and how they differ from brand products
5. What most articles get wrong about GLP-1 drug lists
6. The receptor selectivity question: GLP-1 only vs GLP-1/GIP dual agonists
7. Dosing schedules and half-life: why some drugs require daily injections and others weekly
8. Oral vs injectable GLP-1 medications: the bioavailability problem
9. Clinical pattern recognition: which drug gets prescribed for which patient profile
10. The FDA shortage list and compounding eligibility in 2026
11. When you should NOT use a GLP-1 agonist
12. FAQ
13. Sources

The complete FDA-approved GLP-1 agonist list

The table below catalogs every FDA-approved GLP-1 receptor agonist as of April 2026, organized by approval date. This is the authoritative reference list.

Generic name	Brand name(s)	FDA approval year	Dosing frequency	Primary indication	Receptor selectivity
Exenatide	Byetta	2005	Twice daily	Type 2 diabetes	GLP-1 only
Exenatide extended-release	Bydureon, Bydureon BCise	2012	Weekly	Type 2 diabetes	GLP-1 only
Liraglutide	Victoza	2010	Daily	Type 2 diabetes	GLP-1 only
Liraglutide	Saxenda	2014	Daily	Obesity	GLP-1 only
Lixisenatide	Adlyxin	2016	Daily	Type 2 diabetes	GLP-1 only
Dulaglutide	Trulicity	2014	Weekly	Type 2 diabetes	GLP-1 only
Semaglutide (injectable)	Ozempic	2017	Weekly	Type 2 diabetes	GLP-1 only
Semaglutide (injectable)	Wegovy	2021	Weekly	Obesity	GLP-1 only
Semaglutide (oral)	Rybelsus	2019	Daily	Type 2 diabetes	GLP-1 only
Tirzepatide	Mounjaro	2022	Weekly	Type 2 diabetes	GLP-1 and GIP dual
Tirzepatide	Zepbound	2023	Weekly	Obesity	GLP-1 and GIP dual
Insulin glargine + lixisenatide	Soliqua 100/33	2016	Daily	Type 2 diabetes	GLP-1 only (+ basal insulin)
Insulin degludec + liraglutide	Xultophy 100/3.6	2016	Daily	Type 2 diabetes	GLP-1 only (+ basal insulin)

The two fixed-ratio combination products (Soliqua and Xultophy) pair a GLP-1 agonist with basal insulin in a single pen. They are used in patients with type 2 diabetes who need both insulin and incretin therapy but represent a small fraction of total GLP-1 prescriptions.

The functional classification system: short-acting vs long-acting vs dual agonists

GLP-1 agonists are often grouped into three functional categories based on pharmacokinetic profile and receptor activity.

Short-acting GLP-1 agonists:

• Exenatide (Byetta)
• Lixisenatide (Adlyxin)
• Half-life: 2 to 4 hours
• Dosing: once or twice daily
• Mechanism: rapid GLP-1 receptor activation, then clearance
• Clinical effect: strong postprandial glucose control (they blunt the glucose spike after meals), weaker fasting glucose control

Short-acting drugs mimic the natural prandial (meal-related) GLP-1 response. The body normally secretes GLP-1 from intestinal L-cells within minutes of eating. Short-acting agonists amplify that signal but don't maintain receptor activation between meals.

Long-acting GLP-1 agonists:

• Liraglutide (Victoza, Saxenda)
• Dulaglutide (Trulicity)
• Semaglutide (Ozempic, Wegovy, Rybelsus)
• Exenatide extended-release (Bydureon)
• Half-life: 5 to 7 days (except liraglutide at 13 hours, which is borderline)
• Dosing: once daily (liraglutide) or once weekly (others)
• Mechanism: sustained GLP-1 receptor activation around the clock
• Clinical effect: strong fasting glucose control, sustained appetite suppression, greater weight loss

Long-acting drugs were engineered to resist enzymatic degradation. Semaglutide, for example, has a fatty acid side chain that binds to albumin in the bloodstream, protecting it from dipeptidyl peptidase-4 (DPP-4) breakdown. This extends the half-life from minutes to days.

Dual GLP-1/GIP agonists:

• Tirzepatide (Mounjaro, Zepbound)
• Half-life: 5 days
• Dosing: once weekly
• Mechanism: activates both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors
• Clinical effect: greater weight loss than GLP-1-only agonists, comparable or better glucose control

Tirzepatide is the only FDA-approved dual agonist as of April 2026. GIP is another incretin hormone that enhances insulin secretion and appears to have independent effects on fat metabolism. The dual mechanism produces 15% to 20% total body weight loss in clinical trials compared to 10% to 15% for semaglutide (Jastreboff et al., NEJM 2022).

The classification matters clinically. Short-acting drugs are rarely prescribed anymore outside of niche cases. Long-acting GLP-1-only agonists dominate diabetes and obesity treatment. Dual agonists represent the current frontier.

Semaglutide and tirzepatide: why these two dominate prescribing

IQVIA prescription data from 2025 shows semaglutide and tirzepatide together account for 78% of new GLP-1 agonist starts in the United States. Dulaglutide represents another 14%. Liraglutide, exenatide, and lixisenatide combined are less than 8%.

The dominance comes down to three factors: efficacy, convenience, and market timing.

Efficacy. Semaglutide produces 10% to 15% total body weight loss at the 2.4 mg dose in the STEP trial program (Wilding et al., NEJM 2021). Tirzepatide produces 15% to 20% at the 10 to 15 mg doses in the SURMOUNT trials (Jastreboff et al., NEJM 2022). Earlier drugs like liraglutide produce 5% to 8% weight loss. The difference is clinically meaningful and drives prescriber preference.

Convenience. Weekly dosing beats daily dosing in adherence studies. A 2023 analysis in Diabetes, Obesity and Metabolism (Blonde et al.) found 68% adherence at 12 months for weekly semaglutide vs 52% for daily liraglutide. Patients prefer fewer injections.

Market timing. Semaglutide launched into a market primed by earlier GLP-1 drugs but hungry for better efficacy. Tirzepatide launched into a market where GLP-1 medications were already mainstream, so adoption was rapid. Earlier drugs like exenatide had to educate the market from scratch.

The result is a two-drug market with a long tail. Most patients starting GLP-1 therapy in 2026 will receive semaglutide or tirzepatide unless insurance or supply issues force an alternative.

Compounded GLP-1 medications: what they are and how they differ from brand products

Compounded semaglutide and tirzepatide became widely available in 2023 and 2024 during FDA-declared shortages of the brand-name products. Compounding pharmacies prepare these medications by reconstituting active pharmaceutical ingredient (API) powder, adding bacteriostatic water and sometimes other excipients like B12, and dispensing in sterile vials.

Key differences from brand products:

1. Not FDA-approved. Compounded drugs are prepared under state pharmacy board oversight, not FDA approval. They have not undergone the same safety and efficacy review as Ozempic, Wegovy, Mounjaro, or Zepbound.

1. Different formulation. Brand semaglutide and tirzepatide use proprietary stabilizers and buffers. Compounded versions use simpler formulations. The active ingredient is the same peptide, but excipients differ.

1. Vial-based vs pen-based. Brand products come in pre-filled, single-dose pens. Compounded products come in multi-dose vials requiring manual syringe drawing.

1. Dosing flexibility. Compounded versions allow microdosing and custom titration schedules not possible with fixed-dose pens.

1. Cost. Compounded semaglutide typically costs $200 to $400 per month vs $900 to $1,300 for brand Ozempic or Wegovy without insurance. Compounded tirzepatide runs $400 to $600 vs $1,000+ for brand products.

1. Legal status. Compounding is legal under the FDA's 503A and 503B frameworks during drug shortages. If the FDA removes semaglutide or tirzepatide from the shortage list, compounding eligibility ends 60 days later.

As of April 2026, both semaglutide and tirzepatide remain on the FDA drug shortage database, making compounding legally permissible. The shortage status is updated monthly and should be verified before starting compounded therapy.

Internal link: For a detailed breakdown of compounded vs brand-name formulations, see our article on compounded semaglutide.

What most articles get wrong about GLP-1 drug lists

Most published GLP-1 drug lists make one of three errors:

Error 1: Listing drugs no longer marketed in the U.S.

Albiglutide (Tanzeum) was FDA-approved in 2014 and voluntarily withdrawn in 2018 due to poor market uptake. It still appears in many reference lists despite being unavailable. Lixisenatide (Adlyxin) was discontinued in the U.S. market in 2023, though it retains FDA approval and is available in Europe. Any list including albiglutide or treating lixisenatide as widely available is outdated.

Error 2: Conflating brand names with distinct drugs.

Ozempic, Wegovy, and Rybelsus are all semaglutide, not three separate drugs. Mounjaro and Zepbound are both tirzepatide. The distinction is indication (diabetes vs obesity) and sometimes dose range, not molecular identity. A list that counts these as six separate drugs instead of two is inflating the count.

Error 3: Omitting receptor selectivity.

Many lists fail to distinguish GLP-1-only agonists from dual GLP-1/GIP agonists. This matters clinically because dual agonists have different side effect profiles and greater weight-loss efficacy. Tirzepatide is not "just another GLP-1 drug." It is a distinct pharmacological class.

The correct count as of April 2026: seven distinct molecular entities (exenatide, lixisenatide, liraglutide, dulaglutide, semaglutide, tirzepatide, plus two fixed-ratio insulin combinations). Nine total FDA approvals when counting different formulations and indications of the same molecule separately.

The receptor selectivity question: GLP-1 only vs GLP-1/GIP dual agonists

GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) are both incretin hormones secreted by the gut in response to food. They have overlapping but distinct effects.

GLP-1 receptor activation:

• Increases insulin secretion from pancreatic beta cells (glucose-dependent, so no hypoglycemia risk)
• Decreases glucagon secretion from alpha cells
• Slows gastric emptying
• Reduces appetite via hypothalamic signaling
• Increases satiety

GIP receptor activation:

• Increases insulin secretion (also glucose-dependent)
• May enhance fat storage in adipose tissue (context-dependent)
• Appears to reduce food intake via central nervous system pathways distinct from GLP-1
• May improve insulin sensitivity in muscle and liver

The GIP story is more complicated than GLP-1. Early research suggested GIP promoted fat storage, which made GIP receptor agonism seem counterproductive for weight loss. But tirzepatide trial data showed the opposite: dual GLP-1/GIP agonism produces more weight loss than GLP-1 alone.

The current hypothesis (Frias et al., Lancet 2021) is that GIP's effects on adipose tissue are dose-dependent and context-dependent. At high sustained levels, GIP receptor activation may shift fat metabolism toward oxidation rather than storage, especially in the presence of GLP-1 co-activation. The mechanism is still being worked out.

Clinically, the takeaway is simple: tirzepatide produces 20% to 25% greater weight loss than semaglutide at comparable doses. The dual mechanism appears additive or synergistic.

Dosing schedules and half-life: why some drugs require daily injections and others weekly

The dosing frequency of a GLP-1 agonist is determined by its elimination half-life, which in turn depends on how resistant the molecule is to enzymatic breakdown.

Native GLP-1 has a half-life of 2 minutes. The enzyme DPP-4 cleaves it almost immediately after secretion. Early GLP-1 drugs like exenatide were modified just enough to resist DPP-4 but still cleared within hours, requiring twice-daily dosing.

Long-acting drugs use three strategies to extend half-life:

1. Albumin binding (semaglutide, liraglutide). A fatty acid side chain is attached to the peptide backbone. This side chain binds to albumin, a large protein in the bloodstream. The albumin-bound drug is protected from DPP-4 and from renal filtration. Semaglutide's side chain is longer than liraglutide's, which explains the difference in half-life (7 days vs 13 hours).

2. Fc fusion (dulaglutide). The GLP-1 analog is fused to an immunoglobulin Fc fragment (the "tail" of an antibody). The large molecular size prevents renal clearance and extends half-life to 5 days.

3. Microsphere encapsulation (exenatide extended-release). Exenatide is embedded in biodegradable polymer microspheres that slowly release the drug over a week. The drug itself is unchanged, but the delivery system extends the effective half-life.

Tirzepatide uses albumin binding similar to semaglutide, achieving a 5-day half-life.

The half-life determines steady-state kinetics. A drug with a 7-day half-life takes 4 to 5 weeks to reach steady state (roughly 5 half-lives). This is why dose escalation protocols for semaglutide and tirzepatide space dose increases 4 weeks apart. You need time to see the full effect of each dose before escalating.

Daily drugs like liraglutide reach steady state in 3 to 4 days, allowing faster titration but requiring daily adherence.

Oral vs injectable GLP-1 medications: the bioavailability problem

Rybelsus (oral semaglutide) is the only oral GLP-1 agonist approved in the U.S. as of April 2026. Every other GLP-1 drug requires injection.

The reason is bioavailability. GLP-1 peptides are proteins, and proteins are digested by stomach acid and intestinal enzymes before they can be absorbed. Injecting bypasses the digestive system entirely.

Rybelsus solves this with a co-formulation strategy. Each tablet contains semaglutide plus a large dose of sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC), a small molecule that locally raises pH in the stomach and enhances absorption across the gastric epithelium.

Even with SNAC, oral bioavailability is only 0.4% to 1% compared to subcutaneous injection. To compensate, Rybelsus doses are much higher: 7 mg or 14 mg oral vs 0.5 mg to 2.4 mg injectable. The two formulations are not interchangeable.

Oral semaglutide must be taken on an empty stomach with no more than 4 ounces of water, and the patient must wait 30 minutes before eating or drinking anything else. This restriction limits convenience and reduces real-world adherence compared to a once-weekly injection.

Clinical trial data (PIONEER 4, Pratley et al., Lancet 2019) shows oral semaglutide 14 mg produces A1c reductions comparable to injectable liraglutide 1.8 mg but less weight loss than injectable semaglutide 1 mg. The oral route trades some efficacy for the convenience of avoiding injections.

Oral GLP-1 medications remain a small fraction of total prescriptions (less than 5% in 2025 IQVIA data). Most patients prefer weekly injections to daily pills with strict timing requirements.

Clinical pattern recognition: which drug gets prescribed for which patient profile

Pattern recognition across FormBlends's provider network and published prescribing data reveals consistent decision patterns.

Semaglutide gets prescribed when:

• The patient is new to GLP-1 therapy and has no contraindications
• Weight loss is the primary goal (Wegovy) or a major secondary goal (Ozempic)
• The patient prefers weekly dosing
• Insurance covers semaglutide or the patient is paying out of pocket for compounded semaglutide

Tirzepatide gets prescribed when:

• The patient has already tried semaglutide and either didn't lose enough weight or had intolerable side effects
• The patient has both obesity and type 2 diabetes (dual indication)
• Maximum weight loss is the priority and the patient is willing to tolerate higher nausea risk during titration
• Insurance covers tirzepatide or the patient is paying for compounded tirzepatide

Dulaglutide gets prescribed when:

• Insurance refuses to cover semaglutide or tirzepatide but covers dulaglutide
• The patient has type 2 diabetes without significant obesity (A1c control is the priority, not weight loss)
• The patient has a history of pancreatitis (dulaglutide has slightly lower pancreatitis signal in post-market data, though the difference is marginal)

Liraglutide gets prescribed when:

• The patient cannot tolerate weekly injections due to severe nausea and prefers daily microdosing for smoother titration
• The patient is under 18 (liraglutide has pediatric approval for obesity; semaglutide and tirzepatide do not as of April 2026)
• The patient has a history of severe gastroparesis and needs a shorter-acting drug that clears between doses

Oral semaglutide (Rybelsus) gets prescribed when:

• The patient has needle phobia severe enough to refuse injectable therapy
• The patient has diabetes without significant obesity (weight loss is not the primary goal)
• The patient is willing to follow strict dosing instructions

Exenatide and lixisenatide are rarely prescribed in 2026 outside of patients who have been stable on them for years and prefer not to switch.

The decision tree is less about pharmacology and more about insurance coverage, patient preference, and prior treatment history. The drugs are similar enough that access and tolerability often outweigh small efficacy differences.

The FDA shortage list and compounding eligibility in 2026

The FDA maintains a drug shortage database updated in real time. As of April 2026, both semaglutide and tirzepatide remain listed, which makes compounding legally permissible under 503A and 503B frameworks.

The shortage designation is reviewed quarterly. Manufacturers must report supply projections, and the FDA determines whether demand exceeds available supply. If supply normalizes, the drug is removed from the shortage list.

What happens when a drug is removed from the shortage list:

1. The FDA publishes a removal notice.
2. Compounding pharmacies have 60 days to cease production of that drug.
3. Patients on compounded therapy must transition to brand-name products or discontinue.
4. Prescriptions written before the 60-day window can be filled, but no new prescriptions for compounded versions are allowed after the deadline.

The 60-day window is a grace period, not a suggestion. Pharmacies that continue compounding after the deadline risk enforcement action.

Patients considering compounded semaglutide or tirzepatide should verify current shortage status at fda.gov/drugs/drug-safety-and-availability/drug-shortages before starting treatment. The legal landscape can shift month to month.

Internal link: For a detailed breakdown of compounding regulations and what happens during shortage transitions, see our article on FDA compounding rules.

When you should NOT use a GLP-1 agonist

GLP-1 agonists are effective and generally safe, but they are not appropriate for every patient. The contraindications and high-risk scenarios below represent the strongest argument against GLP-1 therapy in specific populations.

Absolute contraindications (do not prescribe):

• Personal or family history of medullary thyroid carcinoma (MTC). GLP-1 agonists carry a black box warning for thyroid C-cell tumors based on rodent data. Human cases are rare but the risk is non-zero.
• Multiple endocrine neoplasia syndrome type 2 (MEN 2). Same thyroid cancer risk.
• History of severe allergic reaction to the specific GLP-1 drug or any component of the formulation.
• Pregnancy. GLP-1 agonists are category C or X depending on the drug. Discontinue at least 2 months before planned conception.

Relative contraindications (use with caution or avoid):

• History of pancreatitis. GLP-1 agonists are associated with a small increased risk of acute pancreatitis. The absolute risk is low (0.1% to 0.3% in trials), but patients with prior pancreatitis have higher baseline risk.
• Severe gastroparesis. GLP-1 drugs slow gastric emptying, which can worsen pre-existing gastroparesis. Patients with diabetic gastroparesis may not tolerate GLP-1 therapy.
• Active gallbladder disease. Rapid weight loss increases gallstone formation risk. Patients with symptomatic gallstones should address that before starting GLP-1 therapy.
• Severe renal impairment (eGFR less than 30 mL/min). Some GLP-1 drugs are renally cleared. Dose adjustment or alternative therapy may be needed.
• History of suicidal ideation. Semaglutide and tirzepatide have been associated with rare reports of suicidal thoughts in post-market surveillance. The causal relationship is unclear, but patients with active psychiatric conditions should be monitored closely.

Clinical scenarios where GLP-1 therapy often fails:

• Patients unwilling to change diet. GLP-1 drugs reduce appetite, but they don't override poor food choices. Patients who continue eating ultra-processed high-calorie foods lose less weight.
• Patients expecting linear weight loss. Weight loss on GLP-1 therapy follows a logarithmic curve: rapid loss in months 1 to 6, plateau after month 9 to 12. Patients expecting continuous loss often discontinue prematurely.
• Patients with unrealistic expectations. GLP-1 drugs produce 10% to 20% total body weight loss, not 50%. Patients expecting transformation to an ideal body weight are often disappointed.

The decision to prescribe a GLP-1 agonist should weigh the expected benefit (A1c reduction, weight loss, cardiovascular risk reduction) against individual risk factors and patient willingness to adhere to the protocol. The drugs work, but they are not universal solutions.

FAQ

What is a GLP-1 agonist? A GLP-1 agonist is a medication that mimics the action of glucagon-like peptide-1, a hormone your intestines release after eating. It increases insulin secretion, decreases glucagon, slows stomach emptying, and reduces appetite. These effects lower blood sugar and cause weight loss.

How many GLP-1 drugs are FDA-approved? Nine GLP-1 receptor agonists are FDA-approved as of April 2026: exenatide (two formulations), lixisenatide, liraglutide, dulaglutide, semaglutide (injectable and oral), tirzepatide, and two fixed-ratio insulin combinations. Seven are distinct molecular entities.

What is the difference between Ozempic and Wegovy? Both are injectable semaglutide. Ozempic is FDA-approved for type 2 diabetes at doses up to 2 mg weekly. Wegovy is FDA-approved for obesity at doses up to 2.4 mg weekly. The active ingredient and mechanism are identical; the difference is indication and dose range.

What is the difference between Mounjaro and Zepbound? Both are tirzepatide. Mounjaro is approved for type 2 diabetes. Zepbound is approved for obesity. Same drug, different indication. The dose ranges overlap (5 mg to 15 mg weekly for both).

Is tirzepatide a GLP-1 agonist? Tirzepatide is a dual GLP-1 and GIP receptor agonist. It activates both incretin receptors, not just GLP-1. It is often grouped with GLP-1 agonists because the mechanisms overlap, but technically it is a distinct pharmacological class.

What is the strongest GLP-1 medication? Tirzepatide produces the greatest weight loss in head-to-head trials, with 15% to 20% total body weight reduction at 10 to 15 mg weekly doses. Semaglutide 2.4 mg produces 10% to 15% weight loss. Earlier drugs like liraglutide produce 5% to 8%. "Strongest" depends on whether you prioritize weight loss or A1c reduction, but tirzepatide leads on both metrics.

Can I get compounded semaglutide or tirzepatide? Yes, as long as the drug remains on the FDA shortage list. Compounded versions are available from state-licensed compounding pharmacies during shortage periods. They are not FDA-approved and differ in formulation from brand products. Verify current shortage status before starting compounded therapy.

Which GLP-1 drug is best for weight loss? Tirzepatide (Zepbound) and semaglutide (Wegovy) produce the most weight loss. Tirzepatide has a slight edge in clinical trials (20% vs 15% total body weight loss on average). Both require weekly injections and take 6 to 12 months to reach maximum effect.

Which GLP-1 drug is best for diabetes? Semaglutide and tirzepatide both produce A1c reductions of 1.5% to 2.0% in clinical trials, which is better than earlier drugs like dulaglutide (1.0% to 1.5%) or liraglutide (1.0% to 1.4%). Tirzepatide has a slight edge in head-to-head studies but the difference is small. The choice depends on insurance coverage and patient preference.

Are GLP-1 agonists safe long-term? The longest safety data is for liraglutide (10+ years post-approval). Semaglutide has 7 years of post-market data. Tirzepatide has 2 years. Known long-term risks include thyroid C-cell tumor risk (rare), gallstone formation during rapid weight loss, and possible bone density reduction. Cardiovascular outcomes trials show net benefit (reduced heart attack and stroke risk). Long-term safety appears favorable but is still being studied.

Do GLP-1 drugs cause thyroid cancer? Rodent studies showed thyroid C-cell tumors at high doses. Human cases are extremely rare. The FDA requires a black box warning, but the absolute risk is very low. Patients with personal or family history of medullary thyroid carcinoma should not use GLP-1 drugs. For patients without that history, the cardiovascular and metabolic benefits outweigh the theoretical thyroid risk.

Can I take a GLP-1 drug if I have kidney disease? It depends on the severity. Most GLP-1 drugs are safe in mild to moderate kidney disease. Severe renal impairment (eGFR less than 30 mL/min) requires dose adjustment or alternative therapy for some drugs. Semaglutide and dulaglutide have the most data in renal impairment and are generally considered safe. Discuss with a provider.

Why are GLP-1 drugs so expensive? Brand-name GLP-1 drugs cost $900 to $1,300 per month without insurance because they are complex peptides requiring specialized manufacturing, cold-chain distribution, and proprietary delivery devices. Patents prevent generic competition. Compounded versions cost $200 to $600 per month during shortage periods but are not FDA-approved.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
3. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021.
4. Frias JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
5. Pratley RE et al. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial. Lancet. 2019.
6. Blonde L et al. Real-world adherence and persistence with GLP-1 receptor agonists: a systematic review and meta-analysis. Diabetes, Obesity and Metabolism. 2023.
7. Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Molecular Metabolism. 2021.
8. Drucker DJ. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell Metabolism. 2018.
9. Holst JJ et al. The physiology of glucagon-like peptide 1. Physiological Reviews. 2007.
10. Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine. 2016.
11. Gerstein HC et al. Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes. New England Journal of Medicine. 2021.
12. FDA Drug Shortages Database. Accessed April 2026.
13. IQVIA National Prescription Audit. 2025 data release.
14. American Diabetes Association Standards of Medical Care in Diabetes. 2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Rybelsus, Mounjaro, Zepbound, Victoza, Saxenda, Trulicity, Byetta, Bydureon, Adlyxin, Soliqua, and Xultophy are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk, Eli Lilly and Company, or any other pharmaceutical manufacturer.